Glycopyrronium
- Generic Name
- Glycopyrronium
- Brand Names
- Bevespi, Breztri, Cuvposa, Dartisla, Enurev Breezhaler, Glycate, Glyrx, Lonhala, Prevduo, Qbrexza, Robinul, Robinul Forte, Seebri Breezhaler, Sialanar, Tovanor Breezhaler, Ultibro
- Drug Type
- Small Molecule
- Chemical Formula
- C19H28NO3
- CAS Number
- 740028-90-4
- Unique Ingredient Identifier
- A14FB57V1D
- Background
Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications. Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of pept...
- Indication
Glycopyrronium formulated as a topical cloth is indicated to treat primary axillary hyperhidrosis in patients ≥9 years, and an inhalational solution is indicated for long term maintenance of airflow obstruction in COPD. A glycopyrronium intravenous and intramuscular injection is indicated in adults and pediatric patients to reduce the volume and acidity of g...
- Associated Conditions
- Airway Obstruction, Chronic Obstructive Pulmonary Disease (COPD), Increased upper airway secretion, Peptic Ulcer, Primary Axillary Hyperhidrosis, Sialorrhea, Cardiac vagal inhibitory reflexes, Cardiac vagal inhibitory reflexes caused by General Surgery, Cardiac vagal inhibitory reflexes caused by Medication, Gastric secretions, Peripheral muscarinic effects
- Associated Therapies
- -
Conduct Phase III CT: CDSCO Panel Tells Zydus Healthcare on Glycopyrrolatem plus ...
Zydus Healthcare presented a bioequivalence study report to the SEC, which recommended conducting a Phase III clinical trial for the FDC Glycopyrrolate plus Indacaterol Maleate metered dose inhalation for COPD treatment.
Journey Medical Corporation Reports Third Quarter 2024
Journey Medical Corporation announced FDA approval of Emrosi™ for rosacea treatment, expecting launch in Q1-Q2 2025, and reported $14.6 million in Q3 2024 revenues.
Verona Pharma Reports Strong Q3 Launch for COPD Drug
Verona Pharma (VRNA) reported Q3 2024 earnings, with $5.6 million in net sales for its COPD treatment Ohtuvayre. The launch saw over 5,000 prescriptions filled by 2,200 healthcare professionals. The company is conducting two Phase 2 trials and reported a $43 million net loss due to increased R&D and SG&A expenses. Verona Pharma's cash position is $336 million, and management is optimistic about future growth.
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Verona Pharma reports Q3 net sales of $5.6 million for Ohtuvayre™ (ensifentrine), with October sales exceeding Q3. Over 2,200 unique prescribers and 5,000 prescriptions filled for COPD treatment. Two Phase 2 programs initiated, and a conference call scheduled for November 4, 2024.
Verona Pharma Reports Third Quarter 2024 Financial Results
Verona Pharma reports Q3 net sales of $5.6 million for Ohtuvayre (ensifentrine), with October sales exceeding Q3. Over 2,200 prescribers and 5,000 prescriptions filled for COPD treatment. Two Phase 2 programs initiated, and a conference call scheduled for November 4, 2024.
Electroconvulsive Therapy for the Treatment of Dementia Symptoms
Dementia's prevalence and incidence are rising due to aging trends, with no FDA-approved treatments for its behavioral and psychological symptoms. Electroconvulsive therapy (ECT) has shown efficacy in managing these symptoms in dementia patients, with studies indicating reduced agitation and improved memory without worsening cognitive function. Ongoing trials and retrospective analyses support ECT's potential benefits, though randomized trials are lacking. Clinical considerations include consent issues and managing comorbid medical conditions. ECT is deemed safe and may improve cognitive function, making it a viable option in select cases.
AstraZeneca eyes up transition to eco-friendly inhaler propellant
AstraZeneca completed clinical studies for Breztri, its COPD inhaler, transitioning to a next-gen propellant with near-zero global warming potential. First regulatory submissions in Europe, UK, and China expected by end of 2024. Breztri, using eco-friendly HFO-1234ze, aims to reduce carbon footprint and generated $677m in global sales in 2023, with projections to reach $2.14bn by 2030.
AstraZeneca completes clinical trials for near-zero emission inhalers
AstraZeneca completed clinical studies for a new inhaler propellant, HFO-1234ze, reducing greenhouse gas emissions by 99.9%. Breztri, a COPD therapy, will be the first to transition, with regulatory submissions expected in Europe, the UK, and China by end of 2024. This aligns with AstraZeneca's Ambition Zero Carbon strategy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath